{ "@context": "https://schema.org", "@graph": [ { "@type": "LegalCase", "@id": "case-9678", "postId": 9678, "name": "Ardelyx, Inc.", "description": "Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ardelyx To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Ardelyx between January 13, 2025 and August 6, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ardelyx, Inc. (\u201cArdelyx\u201d or the \u201cCompany\u201d) (NASDAQ: ARDX) and reminds investors of the November 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that \u00a0the true state of Ardelyx\u2019s commercial performance and growth prospects for XPHOZAH and IBSRELA, and in particular the increasing payer-related access and reimbursement barriers affecting patient access, more stringent prior authorization requirements and step edit requirements that slowed new-patient starts and delayed prescription fulfillment. Lead Plaintiff Deadline: November 16, 2026 \u00a0Call\u00a0Partner Josh Wilson\u00a0at\u00a0877-247-4292\u00a0or\u00a0212-983-9330 (Ext. 1310) Or\u00a0submit your information below\u00a0to learn about your rights.", "identifier": "ARDX", "legal": { "court": "United States District Court for the District of Massachusetts", "jurisdiction": "Federal (United States), federal securities laws" }, "classPeriod": { "start": "01/13/2025", "end": "08/06/2026" }, "leadPlaintiffDeadline": "11/16/2026", "caseStatus": { "name": "", "slug": "" }, "practiceArea": { "name": "Securities Litigation", "slug": "securities-litigation" }, "url": "https://faruqilaw.com/case/ardelyx-inc/", "canonicalUrl": "https://faruqilaw.com/case/ardelyx-inc/", "datePublished": "2026-09-18T19:21:27+00:00", "dateModified": "2026-09-18T19:21:27+00:00", "associatedOrganization": { "@id": "case-9678-org" }, "legalService": { "@id": "case-9678-legalservice" }, "hasPart": [ { "@id": "case-9678-faq" }, { "@id": "case-9678-press-list" } ], "legalRepresentation": [ { "@id": "case-9678-attorney-516" }, { "@id": "case-9678-attorney-506" } ] }, { "@type": "Organization", "@id": "case-9678-org", "name": "Ardelyx, Inc.", "identifier": "ARDX", "logo": "https://faruqilaw.com/wp-content/uploads/2025/05/logo.svg", "url": "https://ardelyx.com/" }, { "@type": "LegalService", "@id": "case-9678-legalservice", "name": "Faruqi & Faruqi, LLP", "url": "https://faruqilaw.com/", "telephone": "+1-212-983-9330", "logo": "https://faruqilaw.com/wp-content/uploads/2025/05/logo.svg", "address": { "@type": "PostalAddress", "streetAddress": "685 3rd Ave 26th Floor", "addressLocality": "New York", "postalCode": "10017", "addressRegion": "NY", "addressCountry": "US" }, "sameAs": [ "https://faruqilaw.com/", "https://maps.google.com/?cid=3247549158190754383" ] }, { "@type": "Person", "@id": "case-9678-attorney-516", "name": "James M. Wilson, Jr.", "worksFor": { "@id": "case-9678-legalservice" } }, { "@type": "Person", "@id": "case-9678-attorney-506", "name": "Robert W. Killorin", "worksFor": { "@id": "case-9678-legalservice" } }, { "@type": "NewsArticle", "@id": "case-9678-press-1", "headline": "Ardelyx chief human resources officer sells $58,378 in stock", "url": "https://www.investing.com/news/insider-trading-news/ardelyx-chief-human-resources-officer-sells-58378-in-stock-93CH-4876066", "datePublished": "2026-08-25" }, { "@type": "NewsArticle", "@id": "case-9678-press-2", "headline": "Ardelyx (ARDX) Cuts Guidance On Payer Hurdles As Fair Value Debate Heats Up", "url": "https://finance.yahoo.com/healthcare/articles/ardelyx-ardx-cuts-guidance-payer-180834270.html", "datePublished": "2026-08-22" }, { "@type": "NewsArticle", "@id": "case-9678-press-3", "headline": "Ardelyx stock falls 18% after Q2 miss and XPHOZAH target withdrawal", "url": "https://scanx.trade/stock-market-news/companies/ardelyx-stock-falls-18-q2-revenue-miss-guidance-cut/48221736", "datePublished": "2026-08-13" }, { "@type": "NewsArticle", "@id": "case-9678-press-4", "headline": "Ardelyx (ARDX) Posts Record Revenue, Is The Stock Still 70% Undervalued?", "url": "https://finance.yahoo.com/markets/stocks/articles/ardelyx-ardx-posts-record-revenue-151336047.html", "datePublished": "2026-08-07" }, { "@type": "NewsArticle", "@id": "case-9678-press-5", "headline": "Ardelyx: Low Price, But High Implied Valuation", "url": "https://seekingalpha.com/article/4901425-ardelyx-low-price-but-high-implied-valuation", "datePublished": "2026-05-08" }, { "@type": "NewsArticle", "@id": "case-9678-press-6", "headline": "ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%?", "url": "https://stocktwits.com/news-articles/markets/equity/ardx-stock-down-premarket-after-q4-miss-why-did-this-firm-hike-price-target/cZRN5NAR4xB", "datePublished": "2026-03-05" }, { "@type": "ItemList", "@id": "case-9678-press-list", "itemListElement": [ { "@type": "ListItem", "position": 1, "item": { "@id": "case-9678-press-1" } }, { "@type": "ListItem", "position": 2, "item": { "@id": "case-9678-press-2" } }, { "@type": "ListItem", "position": 3, "item": { "@id": "case-9678-press-3" } }, { "@type": "ListItem", "position": 4, "item": { "@id": "case-9678-press-4" } }, { "@type": "ListItem", "position": 5, "item": { "@id": "case-9678-press-5" } }, { "@type": "ListItem", "position": 6, "item": { "@id": "case-9678-press-6" } } ] } ] }

Ardelyx, Inc.

Ardelyx, Inc.

Join Action
Case Details
Ticker ARDX
Class Period 01/13/2025 - 08/06/2026
Lead Plaintiff Deadline 11/16/2026
Days Left to Seek Lead Plaintiff
58

If you are a Ardelyx investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ardelyx To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Ardelyx between January 13, 2025 and August 6, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX) and reminds investors of the November 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that  the true state of Ardelyx’s commercial performance and growth prospects for XPHOZAH and IBSRELA, and in particular the increasing payer-related access and reimbursement barriers affecting patient access, more stringent prior authorization requirements and step edit requirements that slowed new-patient starts and delayed prescription fulfillment.

📞 Lead Plaintiff Deadline: November 16, 2026

💻 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action
Ardelyx, Inc.
1
1
1
1

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Counsel
James M. Wilson, Jr.
jwilson@faruqilaw.com
Phone (212) 983-9330
Fax (212) 983-9331
Robert W. Killorin
rkillorin@faruqilaw.com
Phone (404) 847-0617
Fax (404) 506-9534
Office
New York
685 Third Avenue 26th Floor New York New York 10017
Phone (212) 983-9330
Fax (212) 983-9331

Our Offices

Our offices are nationwide. If you have any questions about a case or our firm, please contact us.
Send Us a Message
New York
685 Third Avenue 26th Floor
New York New York 10017
(877) 247-4292 / (212) 983-9330
(212) 983-9331
Los Angeles
1901 Avenue of the Stars Suite 1060
Los Angeles California 90067
(424) 256-2884
(424) 256-2885
Atlanta
3565 Piedmont Road NE Building Four, Suite 380
Atlanta Georgia 30305
(404) 847-0617
(404) 506-9534
Philadelphia
1617 JFK Boulevard, Suite 1550 Philadelphia
Pennsylvania 19103
(215) 277-5770
(215) 277-5771